Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-19T01:26:54.811Z Has data issue: false hasContentIssue false
  • English
  • Français

Tolerability of antipsychotic drugs: does patients perspective deserve consideration?

Published online by Cambridge University Press:  11 April 2011

Michela Nosè
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

This contribution initially describes some traditional tools that are commonly used to measure drug tolerability, including measures that take into considerations both clinicians’ and patients’ views. Subsequently, it highlights a few studies that compared the patient and clinician's perspective in the evaluation of drug tolerability, trying to understand whether health care providers and patients perceive antipsychotic tolerability in different ways, and whether these different ways may have implica-tions in terms of treatment adherence and outcome. Finally, some clinical and research implications are suggested and discussed.

Type
Editorials
Information
Epidemiology and Psychiatric Sciences , Volume 17 , Issue 3 , September 2008 , pp. 182 - 185
Copyright
Copyright © Cambridge University Press 2008

References

Barbui, C., Nosè, M., Bindman, J., Schene, A., Becker, T., Mazzi, M.A., Kikkert, M., Camara, J., Born, A. & Tansella, M. (2005). Sex differences in the subjective tolerability of antipsychotic drugs. Journal of Clinical Psychopharmacology 25, 521–526.CrossRefGoogle ScholarPubMed
Barbui, C., Cipriani, A., Malvini, L., Nosè, M., Accordini, S., Pontarollo, F., Veronese, A., Tansella, M & CHAT investigators (2006). Trasformare la pratica clinica in ricerca. Un invito a partecipare allo stu-dio CHAT. Rivista di Psichiatria 41, 326–330.Google Scholar
Barnes, T.R.E. (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672–676.CrossRefGoogle ScholarPubMed
Castle, D., Morgan, V. & Jablensky, A. (2002). Antipsychotic use in Australia: the patients’ perspective. Australian & New Zealand Journal of Psychiatry 36(5), 633–641.CrossRefGoogle ScholarPubMed
Day, J.C., Wood, G., Dewey, M. & Bentall, R.P. (1995). A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. British Journal of Psychiatry 166, 650–653.Google Scholar
Day, J.C., Kinderman, P. & Bentall, R. (1998). A comparison of patients’ and prescribers’ beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatrica Scandinavica 97(1), 93–97.CrossRefGoogle ScholarPubMed
Day, J.C., Bentall, R.P., Roberts, C., Randall, F., Rogers, A., Cattell, D., Healy, D., Rae, P. & Power, C. (2005). Attitudes toward antipsychotic medication. Archives of General Psychiatry 62, 717–724.CrossRefGoogle ScholarPubMed
Fenton, W.S., Blyler, C.R. & Heinssen, R.K. (1997). Determinants of medication compliance in schizophrenia: empirical and clinical find-ings. Schizophrenia Bulletin 23, 637–651.CrossRefGoogle Scholar
Finn, S.E., Bailey, J.M., Schultz, R.T. & Faber, R. (1990). Subjective utility ratings of neuroleptic in treating schizophrenia. Psychological Medicine 20, 843–848.Google Scholar
Gray, R., Robson, D. & Bressington, D. (2002). Medication management for people with a diagnosis of schizophrenia. Nursing Time 98, 38–40.Google ScholarPubMed
Hamer, S. & Haddad, P. (2007). Adverse effects of antipsychotics as outcome measures. British Journal of Psichiatry 191, Suppl 50, 64–70.Google Scholar
Huffman, J.C., Blais, M.A. & Pirl, W.F. (2004). A comparison of clinician and patient concerns about antipsychotic side effects: a pilot study. Journal of Nervous and Mental Disorder 192, 328–330.CrossRefGoogle ScholarPubMed
Inada, T., Beasley, C.M., Tanaka, Y. & Walker, D.J. (2003). Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale. International Clinical Psychopharmacology 18, 39–48.Google ScholarPubMed
Kahn, R.S., Fleischhacker, W.W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I.P., Gheorghe, M.D., Rybakowski, J.K., Galderisi, S., Libiger, J., Hummer, M., Dollfus, S., López-Ibor, J.J., Hranov, L.G., Gaebel, W., Peuskens, J., Lindefors, N., Riecher-Rössler, A., Grobbee, D.E. & EUFEST study group (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085–97.Google Scholar
Kampman, O., Laippala, P., Vaananen, J., Koivisto, E., Kiviniemi, P., Kilkku, N. & Lehtinen, K. (2002). Indicators of medication compliance in first episode psychosis. Psychiatry Research 110, 39–48.CrossRefGoogle ScholarPubMed
Lambert, T.J.R., Cock, N., Alcock, J., Kelly, D.L. & Conley, R.R. (2003). Measurement of antipsychotic-induced side effects: support for the validity of self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Human Psychopharmacoly-Clinical and Experimental 18, 405–411.CrossRefGoogle ScholarPubMed
Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Seartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S., Davis, C.E., Lebowitz, B.D., Severe, J., Hsiao, J.K. & Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209–1223.CrossRefGoogle ScholarPubMed
Lingjaerde, O., Ahlfors, V.G. & Dech, P. (1987). The UKU side effect rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic treated patients. Acta Psychiatrica Scandinavica, Supplementum No. 334, 76.Google Scholar
McGorry, P.D. &, Killackey, E.J. (2002). Early intervention in psychosis: a new evidence based paradigm. Epidemiologia e Psichiatria Sociale 11, 237–247.Google Scholar
Morrison, P., Gaskill, D., Meehan, T., Lunney, P., Lawrence, G. & Collings, P. (2000). The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice. Australian & New Zealand Journal of Mental Health Nursing 9, 166–176.Google Scholar
Nosè, M., Barbui, C., Gray, R. & Tansella, M. (2003a). Clinical interventions for treatment non-adherence in psychosis: meta-analysis. British Journal of Psychiatry 183, 197–206.Google Scholar
Nosè, M., Barbui, C. & Tansella, M. (2003b). How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychological Medicine 33, 1149–1160.CrossRefGoogle ScholarPubMed
Simpson, J.A. & Angus, J.W.S (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, Supplementum 212, 11–19.Google Scholar
Vorunganti, L., Cortese, L., Oyewumi, L., Cernovsky, Z., Zirul, S. & Awad, A. (2000). Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 43, 135–145.CrossRefGoogle Scholar